Description
The Infliximab N297A Biosimilar.rMAb is a research grade recombinant Human IgG1, kappa monoclonal antibody that specifically recognizes Human Tumor Necrosis Factor (TNF) similarly to therapeutic Infliximab. Infliximab N297A Biosimilar.rMAb was engineered to code for a replacement of asparagine with alanine at position 297 (N297A) of the Human IgG1 heavy chain to reduce potential nonspecific staining caused by Fc receptor binding. Infliximab is a chimeric recombinant Human IgG1 Anti-Human TNF monoclonal antibody that is used to treat a wide variety of inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, Bechet's disease, psoriasis, septic shock, cachexia, and cancer. Therapeutic Infliximab specifically binds to soluble and transmembrane TNF and neutralizes its biological activity by blocking the binding to its cell surface receptors. It may also bind to transmembrane TNF on cells that produce it and mediate both antibody-dependent (ADCC) and complement-dependent (CDC) cytotoxicity. Infliximab does not bind to or inactivate lymphotoxin (Tumor necrosis factor-beta; TNF-ß). TNF, also known as TNF alpha (TNF-a) or Cachectin, is an ~26 kDa type II transmembrane protein that is encoded by TNF. TNF is a multifunctional cytokine that plays roles in inflammation, immune system development, innate and adaptive immune responses, apoptosis, lipid metabolism, and necrosis of some tumor cells. TNF is variably produced by a wide variety of activated leucocytes, epithelial cells, endothelial cells, and tumor cells. This mediator forms noncovalently bound homotrimers that are expressed on the cell surface. Membrane TNF is enzymatically cleaved from the cell surface by tumor necrosis factor alpha converting enzyme (TACE), also known as ADAM17 and CD156b, into a soluble biologically active trimer of the TNF extracellular domains. TNF mediates its biological activities through binding to cell surface TNF Receptor Type 1 (TNFR1, CD120a) and Type 2 (TNFR2, CD120b), which are widely expressed on normal hemopoietic and nonhemopoietic cells as well as tumor cells. The Infliximab N297A Biosimilar.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unreacted dye was removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Alexa Fluor® 488 fluorochrome emission is collected at the same instrument settings as for fluorescein isothiocyanate (FITC).
3. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. An isotype control should be used at the same concentration as the antibody of interest.
8. This product is provided under an intellectual property license between Life Technologies Corporation and BD Businesses. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, Cell Analysis Business Unit Business Development, 29851 Willow Creek Road, Eugene, OR 97402, USA, Tel: (541) 465-8300. Fax: (541) 335-0504.
9. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
10. Alexa Fluor™ is a trademark of Life Technologies Corporation.
11. For U.S. patents that may apply, see bd.com/patents.
